Karyopharm Therapeutics
198 articles with Karyopharm Therapeutics
-
Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020
9/14/2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts have been selected for poster presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 taking place from September 19-21 . Three abstracts fro
-
BioSpace Movers & Shakers, Sept. 4
9/4/2020
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Karyopharm Announces September 2020 Virtual Investor Conference Participation
9/2/2020
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Michael Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fireside chat at Baird's 2020 Global Healthcare Conference and at the Morgan Stanley 18th Annual Global Healthcare Conference.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/1/2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 29,600 shares of Karyopharm's common stock to seven newly-hired employees
-
Karyopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors
8/31/2020
− Former Senior Vice President of the Oncology Business Unit at Genentech; Brings Over 25 Years of Extensive Leadership and Commercial Experience in the Pharmaceutical Industry −
-
BioSpace Movers & Shakers, Aug. 28
8/28/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Karyopharm's Founder, Sharon Shacham, PhD, Selected as a Finalist for the EY Entrepreneur Of The Year® 2020 Award
8/21/2020
− Dr. Shacham Recognized for Her Contributions to Science and Inspiring Others with Her Vision, Leadership and Achievement
-
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
8/4/2020
Second Quarter 2020 XPOVIO Net Product Sales of $18.6 Million; Strongest Quarterly Sales Since July 2019 Launch
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2020
8/3/2020
Karyopharm Therapeutics Inc., an innovation-driven pharmaceutical company, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharm's common stock to three newly-hired employees, with a grant date of July 31, 2020.
-
Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
7/28/2020
Conference Call Scheduled for Tuesday, August 4, 2020, at 8:30 a.m. ET
-
The U.S. Food and Drug Administration greenlit Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) under accelerated approval.
-
Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.
-
Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets
5/5/2020
Antengene Corporation announced a broadened partnership and territory expansion agreement with Karyopharm Therapeutics Inc. for development and commercialization of four oral novel drugs and drug candidates to support its mission of treating patients beyond borders.
-
PROMETRIKA and Karyopharm: Partners in Global COVID-19 Trial
4/30/2020
Cambridge, MA-based clinical research organization to be responsible for Clinical Trial Site Management and On-Site Monitoring in the United States
-
Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19
4/22/2020
Precision for Medicine, a pioneer in the design, development and execution of biomarker-informed clinical studies and complex data management, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) to help conduct the first global randomized clinical trial for low dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
-
Clinical Catch-Up: March 2-6
3/9/2020
It was a relatively quiet week for clinical trial announcements. Here’s a look. -
Research Studies Progressing Towards New FDA Approved Treatments for Glioblastoma
3/3/2020
Although there is presently no cure for glioblastoma, researchers are continually inching closer to new and effective treatment options.
-
Karyopharm Therapeutics posted positive Phase III results in multiple myeloma and announced it is planning a regulatory submission in the second quarter of this year for its combination of Xpovio, Velcade and Dexamethasone.